Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation

Sclerostin negatively regulates bone formation by antagonizing Wnt signalling. An antibody targeting sclerostin for the treatment of postmenopausal osteoporosis was approved by the U.S. Food and Drug Administration, with a boxed warning for cardiovascular risk. Here we demonstrate that sclerostin pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yuanyuan, Wang, Luyao, Ni, Shuaijian, Li, Dijie, Liu, Jin, Chu, Hang Yin, Zhang, Ning, Sun, Meiheng, Li, Nanxi, Ren, Qing, Zhuo, Zhenjian, Zhong, Chuanxin, Xie, Duoli, Li, Yongshu, Zhang, Zong-Kang, Zhang, Huarui, Li, Mei, Zhang, Zhenlin, Chen, Lin, Pan, Xiaohua, Xia, Weibo, Zhang, Shu, Lu, Aiping, Zhang, Bao-Ting, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307627/
https://www.ncbi.nlm.nih.gov/pubmed/35869074
http://dx.doi.org/10.1038/s41467-022-31997-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307627/
https://www.ncbi.nlm.nih.gov/pubmed/35869074
http://dx.doi.org/10.1038/s41467-022-31997-8

Ejemplares similares